CRSP vs ACLX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRSP Captures Institutional Edge (2โ2 Pillars ยท 5โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CRISPR Therapeutics AG (CRSP) driven by superior Valuation, Growth & Margin while ACLX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRSP trades at 23.4x Forward P/E with -2058.6% operating margin (+1325.1% YoY revenue) versus ACLX at 61.7x Forward P/E and -3850.2% operating margin (-89.2% YoY). In options structure, CRSP sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against ACLX sits in UNCLASSIFIED (1st %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRSP | ACLX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.1B | $6.7B | Larger Scale | ACLX |
| Trailing P/E Ratio Valuation | 23.4x | 61.7x | Lower Multiple | CRSP |
| Forward P/E Ratio Valuation | 23.4x | 61.7x | Lower Multiple | CRSP |
| Revenue Growth (YoY) Growth | +1325.1% | -89.2% | Higher Growth | CRSP |
| Operating Margin (TTM) Profitability | -2058.6% | -3850.2% | Higher Margin | CRSP |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -25.6% | -53.4% | Higher ROE | CRSP |
| 52-Week Range Position Momentum | 1% ($40โ$63) | 100% ($48โ$115) | Stronger Trend | ACLX |
| Beta / 30D Volatility Risk Regime | 1.85ฮฒ ยท 60% Vol | -0.83ฮฒ ยท 1% Vol | Lower Realized Risk | ACLX |
| Unified Institutional Score Composite Signal | 48.6 / 100 (HOLD) | 61.7 / 100 (BUY) | Higher Composite | ACLX |